Karachi: The Searle Company Limited, a key player in the pharmaceutical sector, has published its financial results for the fiscal year 2025, amidst a stable global pharmaceutical market projected to reach USD 1.65-1.75 trillion by 2024-25. On November 27, 2025, during a corporate briefing session, the company detailed its financial standing and future prospects.
The Pakistani pharmaceutical industry, although only accounting for approximately 0.2% of the global market with a size of USD 3.7 billion, remains a crucial sector for The Searle Company Limited. The company operates six manufacturing facilities, equally distributed between Karachi and Lahore, producing a range of pharmaceutical and consumer products. The utilisation rates of these facilities indicate a strong operational capacity, with injectables and powders leading at 84% and 83%, respectively.
In FY 2025, The Searle Company Limited reported net sales of 24.77 billion PKR, a decrease of 4.08% from the previous year, marking a moderate move. Despite a decrease in sales, the company achieved a gross profit of 12.59 billion PKR. The net profit after tax amounted to 434.04 million PKR, reflecting a 20.19% growth, classified as a very large or significant move, compared to the previous fiscal year’s loss.
According to information available from the Pakistan Stock Exchange (PSX), The Searle Company Limited maintains significant holdings in both listed and unlisted subsidiaries. These include a 50.2% stake in Searle Biosciences Private Limited and a 74.2% holding in IBL HealthCare Limited, among others. The company’s strategic investments extend into diverse sectors, with notable holdings in distribution, logistics, information technology, and retail.
The Searle Company Limited also highlighted its strategic focus on the burgeoning Asia-Pacific market, driven by rapid expansion in China. The company aligns with global trends such as the increasing demand for advanced therapies and home-based care, propelled by an ageing population and rising cases of chronic diseases.
The company’s P&L statement for FY 2025 reveals an operating profit of 3.69 billion PKR, despite facing challenges in marketing and distribution expenses, which totaled 7.42 billion PKR. The finance costs reduced significantly to 2.03 billion PKR, aiding the bottom line. The net profit margin stood at 1.75%, reflecting a recovery from the previous year’s negative margin.
The balance sheet for FY 2025 shows total equity of 30.24 billion PKR, supported by a robust general reserve and unappropriated profit. The company continues to manage its liabilities efficiently, with a significant reduction in non-current liabilities to 161.96 million PKR.
As part of its future strategy, The Searle Company Limited remains committed to capitalising on global market trends and expanding its footprint in the pharmaceutical and healthcare industries. The company aims to leverage its strong production capabilities and strategic investments to enhance shareholder value and sustain growth.